Celgene-CELG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG

CELG 108.24

0.0%

Nov 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (183)	12/1/1998 5:16:00 PM
From: Mike K	Read Replies (1) of 804

Peter and Thread! Some clarification regarding Multiple Myeloma. Current incidence rate is approximately 3-4 per 100,000 in the US, Canada and Europe. Asian countries have a lower rate of approx. 2 per 100,000. Although the median survival is around 2 years MANY patients today have had the disease for many years. I know several who have had the illness for over 10 years with very little treatment. The point is this is usually a slow moving cancer of the bone marrow. More specifically, it is uncontrolled growth of plasma cells. The transplants referred to in the Arkansas studies are Autologous Peripheral Blood Stem Cell Transplants. The patients were their own donors. The patients in the Arkansas study have advanced disease. Of particular interest to researchers in several centers are the effects of Thalidomide on newly diagnosed early stage patients. Many hem/oncs are excited about this drug including my own. Cheers, Mike dx Smoldering IgD Myeloma, 4/97 Part of phase 1 Gene Therapy study long Celg & Sugn

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next